Product image of Kadefungin 3 (Clotrimazole) supplied by GNH India

Kadefungin 3

Active Ingredient:
Clotrimazole
Origin:
EU

Kadefungin 3 (Clotrimazole)

Clotrimazole, the active ingredient in Kadefungin 3, is an imidazole antifungal presented as a vaginal formulation for vaginal use. It treats vaginal candidiasis, commonly known as yeast infection, in adult women by targeting the fungal cells that cause symptoms such as itching, discharge, and irritation.

GNH India supplies Kadefungin 3 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets. The company follows stringent manufacturing standards and provides reliable logistics for timely delivery to healthcare providers.

Manufacturer / TM Owner

Dr. Kade Pharmazeutische Fabrik Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Clotrimazole is an imidazole antifungal used to treat infections caused by Candida species in the vaginal mucosa.
  • Vaginal candidiasis: alleviates symptoms and eradicates yeast infection in women.
  • Vulvovaginal candidiasis: restores normal vaginal flora and reduces recurrence risk.
  • Candida infection of the vagina: provides targeted antifungal activity to clear the pathogen.

How It Works

  • Clotrimazole inhibits the fungal enzyme lanosterol 14α-demethylase, a cytochrome P450 isoform essential for converting lanosterol to ergosterol. By blocking ergosterol synthesis, the drug disrupts the fungal cell membrane structure, increasing permeability and leading to cell death or growth inhibition.

Side Effects

Clotrimazole is generally well tolerated, but local reactions may occur.

Common Side Effects

  • Burning or stinging sensation at the application site.
  • Mild itching or irritation of the vaginal mucosa.
  • Redness or slight swelling of the treated area.
  • Vaginal discharge that is watery or slightly cloudy.
  • Dryness or a feeling of tightness in the vagina.

Serious or Rare Side Effects

  • Allergic reaction presenting as rash, hives, or swelling of the face and throat.
  • Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Anaphylaxis with difficulty breathing or rapid heartbeat.
  • Persistent or worsening irritation that does not improve after several days.

Precautions & Warnings

  • Before using Kadefungin 3, consider the following safety measures.
  • Pregnancy: consult a healthcare professional before use.
  • Breastfeeding: discuss potential risks with a doctor.
  • Allergy: avoid if you have known hypersensitivity to clotrimazole or other imidazoles.
  • Concurrent vaginal products: do not use other intravaginal medications simultaneously without guidance.
  • Medical conditions: inform your provider of any liver disease or severe systemic illness.
  • Store at room temperature: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Clotrimazole may interact with other medicines; monitor as indicated.

Major Interactions (Avoid)

  • Systemic azole antifungals (e.g., fluconazole): concurrent use can increase toxicity.
  • Strong CYP450 inhibitors (e.g., ketoconazole): may raise systemic exposure.

Moderate Interactions (Monitor Closely)

  • Hormonal contraceptives: topical clotrimazole may slightly reduce effectiveness.
  • Topical corticosteroids: may increase local absorption of clotrimazole.
  • Other intravaginal medications: monitor for irritation or reduced efficacy.

Frequently Asked Questions

Kadefungin 3 contains clotrimazole and is indicated for the treatment of vaginal candidiasis, a common yeast infection in women. It is applied directly to the vaginal area to relieve symptoms such as itching, burning, and abnormal discharge by eliminating the underlying fungal cause.

Clotrimazole blocks the fungal enzyme lanosterol 14α‑demethylase, which is required for producing ergosterol, an essential component of the fungal cell membrane. Without ergosterol, the membrane becomes defective, leading to increased permeability and ultimately inhibiting fungal growth or causing cell death.

The specific dosing regimen for Kadefungin 3 is determined by the prescribing healthcare professional based on the severity of infection and patient factors. Patients should follow the instructions provided by their clinician and the product label, and not alter the dose without medical advice.

Safety data for clotrimazole use during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Kadefungin 3.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kadefungin 3 (clotrimazole) belongs to the imidazole class, offering a broad spectrum against Candida species. Compared with miconazole, another common topical antifungal, clotrimazole has a similar efficacy profile but may differ in formulation options and patient tolerance. Choice of therapy often depends on local guidelines, availability, and individual patient response.

Store Kadefungin 3 at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and effectiveness throughout its shelf life.

Kadefungin 3 is applied intravaginally. The patient inserts the supplied dose into the vagina using the applicator or as directed by the prescriber, typically once daily for the period specified by the healthcare professional.

The most serious risks include allergic reactions such as rash, hives, facial swelling, or anaphylaxis, and rare severe skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any signs of a severe hypersensitivity reaction.

Individuals with a known hypersensitivity to clotrimazole, other imidazole antifungals, or any component of the formulation should avoid using Kadefungin 3. It is also contraindicated in patients who have experienced severe allergic reactions to similar topical antifungal products.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Clotrimazole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT